Your browser doesn't support javascript.
loading
MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han, Jinil; Choi, Yoon-La; Kim, Haein; Choi, Jun Young; Lee, Se Kyung; Lee, Jeong Eon; Choi, Joon-Seok; Park, Sarah; Choi, Jong-Sun; Kim, Young Deug; Nam, Seok Jin; Nam, Byung-Ho; Kwon, Mi Jeong; Shin, Young Kee.
Afiliación
  • Han J; Gencurix, Inc., Seoul, 08394, Korea.
  • Choi YL; Laboratory of Cancer Genomics and Molecular Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06356, Korea.
  • Kim H; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06356, Korea.
  • Choi JY; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, 06356, Korea.
  • Lee SK; Laboratory of Molecular Pathology and Cancer Genomics, Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Korea.
  • Lee JE; Laboratory of Molecular Pathology and Cancer Genomics, Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Korea.
  • Choi JS; Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06356, Korea.
  • Park S; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, 06356, Korea.
  • Choi JS; Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06356, Korea.
  • Kim YD; College of Pharmacy, Catholic University of Daegu, Gyeongbuk, 38430, Korea.
  • Nam SJ; The Center for Anti-cancer Companion Diagnostics, Bio-MAX/N-Bio, Seoul National University, Seoul, 08826, Korea.
  • Nam BH; The Center for Anti-cancer Companion Diagnostics, Bio-MAX/N-Bio, Seoul National University, Seoul, 08826, Korea.
  • Kwon MJ; R&D center, ABION Inc., Seoul, 08394, Korea.
  • Shin YK; Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06356, Korea.
Breast Cancer Res Treat ; 164(1): 41-56, 2017 Jul.
Article en En | MEDLINE | ID: mdl-28409241
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pronóstico / Neoplasias de la Mama / Receptor ErbB-2 / Antígenos CD2 / Metaloproteinasa 11 de la Matriz Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2017 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pronóstico / Neoplasias de la Mama / Receptor ErbB-2 / Antígenos CD2 / Metaloproteinasa 11 de la Matriz Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2017 Tipo del documento: Article Pais de publicación: Países Bajos